跳至主要内容
临床试验/NCT07166133
NCT07166133招募中不适用

GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study

W.L.Gore & Associates18 个研究点 分布在 1 个国家目标入组 125 人开始时间: 2026年3月2日最近更新:
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
125
试验地点
18
主要终点
Lesion rupture (treated area)

研究概览

简要总结

A prospective multi-center post-market study collecting outcomes through at least 5-years and up to 10-years post procedure for subjects treated with the TBE Device in Zone 0/1 as part of routine clinical practice.

详细描述

Minimum of 125 total subjects with a TBE Device implantation procedure initiated in up to 50 Sites in the United States. Subjects will have follow-up at 1 Month, 6 Month, 1 Year, and annually thereafter for a minimum of 5-years and up to a maximum of 10 years.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient or legally authorized representative (LAR) provides written authorization and/or consent per institution and geographical requirements.
  • Patient has been or is intended to be treated with the TBE Device in Zone 0 or Zone
  • Patient is age ≥ 18 years at time of informed consent signature.

排除标准

  • Patient who is, at the time of consent, unlikely to be available for defined follow-up visits.
  • Patient with exclusion criteria required by local law.
  • Patient is currently enrolled in or plans to enroll in any concurrent investigational drug and/or investigational device study within 12 months of study enrollment. Subjects cannot be enrolled in another Gore study.

研究组 & 干预措施

GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device)

Other

干预措施: GORE® TAG® Thoracic Branch Endoprosthesis (Device)

结局指标

主要结局

Lesion rupture (treated area)

时间窗: Minimum of 60 months and up to a maximum 120 months

Rupture in the treated segment of the vessel (e.g., aorta or branch) verified with direct observation or CT / CTA scan.

Loss of aortic or branch patency

时间窗: Minimum of 60 months and up to a maximum of 120 months

No flow or contrast detected through the implanted aortic component or endovascular branch component confirmed with imaging and/or direct observation.

Device Technical Success (index procedure only)

时间窗: Index Endovascular Procedure Only

* Successful access, delivery, and accurate deployment of the device to the intended location, and retrieval of the delivery system. * Patency of the endovascular aortic and side branch components. * The absence of any unanticipated additional corrective procedure related to the device, procedure, or withdrawal of the delivery system.

Lesion-related mortality

时间窗: Within 30 days of surgical revascularization or within 30 days of index endovascular procedure

Death meeting at least one of the following characteristics: * Death during the hospitalization or within 30 days following the surgical revascularization procedure. * Death during the hospitalization or within 30 days following the index endovascular procedure or following conversion to open repair. * Death during the hospitalization or within 30 days following a complication from a secondary procedure associated with the index lesion or study device. * Any death where the treated disease / index lesion or study device caused or significantly contributed to the death, including lesion-rupture, aortic-related complications, disease progression involving the index lesion.

Disabling Stroke

时间窗: Within 30 days of surgical revascularization or within 30 days of index endovascular procedure

Stroke is the acute onset of symptoms consistent with focal or multifocal central nervous system (CNS) injury caused by vascular blockage resulting in ischemia or vascular rupture resulting in hemorrhage, that: * Is identified within 30-days following the surgical revascularization procedure or within 30-days following the index endovascular procedure -AND- * Persists for ≥ 24 hours or until death, or has symptoms lasting \< 24 hours, with pathology or neuroimaging confirmation of CNS infarction -AND- * Has an mRS ≥ 2 with an increase from baseline of at least one grade due to neurological deficits at no more than 120 days post index endovascular procedure.

Permanent Paraplegia (within 30-days)

时间窗: Within 30 days of index endovascular procedure

Paraplegia secondary to Spinal Cord Ischemia identified within 30 days following the index endovascular procedure combined with Spinal Cord Ischemia scale grade = 3 at the one-month follow-up visit. Paraplegia will be assessed using the SVS spinal cord ischemia grading system

Permanent Paraparesis (within 30-days)

时间窗: Within 30 days of index endovascular procedure

Paraparesis secondary to Spinal Cord Ischemia identified within 30 days following the index endovascular procedure, combined with Spinal Cord Ischemia scale grade = 2 at the one-month follow-up visit. Paraparesis will be assessed using the SVS spinal cord ischemia grading system.

New onset renal failure (within 30-days) requiring on-going dialysis

时间窗: Within 30 days of index endovascular procedure

New onset of sustained renal failure identified within 30 days following the index endovascular procedure, combined with requiring dialysis at the 1-Month follow-up visit.

Endoleaks

时间窗: Minimum of 60 months and up to a maximum of 120 months

Perfusion of a treated lesion via: * Type I endoleak is defined as a sealing failure at one of the attachment zones of the graft to the vessel wall, whereby arterial flow perfuses the treated lesion via a perigraft channel: * Type Ia: Proximal aortic attachment zone * Type Ib: Distal aortic attachment zone * Type Ic: Distal attachment zone for branch component. * Type II: Retrograde flow from native aortic branch arteries. * Type III endoleak: Component disconnection or fabric disruption resulting in arterial flow into the perigraft space: * Type IIIa: Attachment of aortic components (aortic-aortic) * Type IIIb: Fabric tear or disruption * Type IIIc: Attachment of aortic component-side-branch or side-branch-side-branch. * Type IV: Late endoleak due to flow through porous fabric. * Type V/Endotension: Aneurysm sac enlargement \> 5 mm with no imaging evidence of an endoleak. * Indeterminate: Endoleak is identified, but source cannot be ascertained.

Reintervention

时间窗: Minimum of 60 months and up to a maximum of 120 months

Additional surgical or interventional procedure related to the treated disease / index lesion, the study device, or to the treatment / procedure. This may include surgical or interventional treatment for endoleaks, disease progression, procedures on the branch to improve or restore patency, spinal drains for Spinal Cord Injury (SCI) management, or conversion to open surgery. Events will not include access site(s) complications, interventions to address issues related to non-treated area of the index lesion, such as bare stent implantation to address bowel ischemia associated with aortic dissection.

Lesion rupture (treated area)

时间窗: Minimum of 60 months and up to a maximum 120 months

Rupture in the treated segment of the vessel (e.g., aorta or branch) verified with direct observation or CT / CTA scan.

Number of subjects with index endovascular procedure initiated after (or following) the surgical revascularization procedure

时间窗: Index Endovascular Procedure Only

Great vessel surgical revascularization procedure is completed, and the endovascular implantation procedure is initiated for the implantation of the TBE Device, without interim death or study discontinuation.

Device Technical Success (index procedure only)

时间窗: Index Endovascular Procedure Only

* Successful access, delivery, and accurate deployment of the device to the intended location, and retrieval of the delivery system. * Patency of the endovascular aortic and side branch components. * The absence of any unanticipated additional corrective procedure related to the device, procedure, or withdrawal of the delivery system.

Lesion-related mortality

时间窗: Within 30 days of surgical revascularization or within 30 days of index endovascular procedure

Death meeting at least one of the following characteristics: * Death during the hospitalization or within 30 days following the surgical revascularization procedure. * Death during the hospitalization or within 30 days following the index endovascular procedure or following conversion to open repair. * Death during the hospitalization or within 30 days following a complication from a secondary procedure associated with the index lesion or study device. * Any death where the treated disease / index lesion or study device caused or significantly contributed to the death, including lesion-rupture, aortic-related complications, disease progression involving the index lesion.

Disabling Stroke

时间窗: Within 30 days of surgical revascularization or within 30 days of index endovascular procedure

Stroke is the acute onset of symptoms consistent with focal or multifocal central nervous system (CNS) injury caused by vascular blockage resulting in ischemia or vascular rupture resulting in hemorrhage, that: * Is identified within 30-days following the surgical revascularization procedure or within 30-days following the index endovascular procedure -AND- * Persists for ≥ 24 hours or until death, or has symptoms lasting \< 24 hours, with pathology or neuroimaging confirmation of CNS infarction -AND- * Has an mRS ≥ 2 with an increase from baseline of at least one grade due to neurological deficits at no more than 120 days post index endovascular procedure.

Permanent Paraplegia (within 30-days)

时间窗: Within 30 days of index endovascular procedure

Paraplegia secondary to Spinal Cord Ischemia identified within 30 days following the index endovascular procedure combined with Spinal Cord Ischemia scale grade = 3 at the one-month follow-up visit. Paraplegia will be assessed using the SVS spinal cord ischemia grading system

Permanent Paraparesis (within 30-days)

时间窗: Within 30 days of index endovascular procedure

Paraparesis secondary to Spinal Cord Ischemia identified within 30 days following the index endovascular procedure, combined with Spinal Cord Ischemia scale grade = 2 at the one-month follow-up visit. Paraparesis will be assessed using the SVS spinal cord ischemia grading system.

New onset renal failure (within 30-days) requiring on-going dialysis

时间窗: Within 30 days of index endovascular procedure

New onset of sustained renal failure identified within 30 days following the index endovascular procedure, combined with requiring dialysis at the 1-Month follow-up visit.

Loss of aortic or branch patency

时间窗: Minimum of 60 months and up to a maximum of 120 months

No flow or contrast detected through the implanted aortic component or endovascular branch component confirmed with imaging and/or direct observation.

Endoleaks

时间窗: Minimum of 60 months and up to a maximum of 120 months

Perfusion of a treated lesion via: * Type I endoleak is defined as a sealing failure at one of the attachment zones of the graft to the vessel wall, whereby arterial flow perfuses the treated lesion via a perigraft channel: * Type Ia: Proximal aortic attachment zone * Type Ib: Distal aortic attachment zone * Type Ic: Distal attachment zone for branch component. * Type II: Retrograde flow from native aortic branch arteries. * Type III endoleak: Component disconnection or fabric disruption resulting in arterial flow into the perigraft space: * Type IIIa: Attachment of aortic components (aortic-aortic) * Type IIIb: Fabric tear or disruption * Type IIIc: Attachment of aortic component-side-branch or side-branch-side-branch. * Type IV: Late endoleak due to flow through porous fabric. * Type V/Endotension: Aneurysm sac enlargement \> 5 mm with no imaging evidence of an endoleak. * Indeterminate: Endoleak is identified, but source cannot be ascertained.

Reintervention

时间窗: Minimum of 60 months and up to a maximum of 120 months

Additional surgical or interventional procedure related to the treated disease / index lesion, the study device, or to the treatment / procedure. This may include surgical or interventional treatment for endoleaks, disease progression, procedures on the branch to improve or restore patency, spinal drains for Spinal Cord Injury (SCI) management, or conversion to open surgery. Events will not include access site(s) complications, interventions to address issues related to non-treated area of the index lesion, such as bare stent implantation to address bowel ischemia associated with aortic dissection.

次要结局

  • Access-related complications (index endovascular procedure only)(Index endovascular procedure only)
  • Life threatening bleed (index endovascular procedure only)(Index endovascular procedure only)
  • Stroke(Minimum of 60 months and up to a maximum of 120 months)
  • Transient Ischemic Attack (TIA)(Minimum of 60 months and up to a maximum of 120 months)
  • Paraplegia (within 30-days)(Within 30 days of index endovascular procedure)
  • Paraparesis (within 30-days)(Within 30 days of index endovascular procedure)
  • Distal device-related thromboembolic adverse event requiring intervention or surgery (through 1-Month)(Through 1 Month of index endovascular procedure)
  • Myocardial infarction (within 30-days)(Within 30 days of surgical revascularization procedure or within 30 days of index endovascular procedure)
  • Laryngeal or Phrenic Nerve injury (within 30-days)(Within 30 days of surgical revascularization or within 30 days of index endovascular procedure)
  • Fistula formation(Minimum of 60 months and up to a maximum of 120 months)
  • Upper extremity ischemia(Minimum of 60 months and up to a maximum of 120 months)
  • Lesion enlargement (treated area)(Minimum of 60 months and up to maximum of 120 months)
  • Device migration(Minimum of 60 months and up to a maximum of 120 months)
  • New dissection (with / without treatment)(Minimum of 60 months and up to maximum of 120 months)
  • Device integrity events (e.g., fracture, kinking, compression)(Minimum of 60 months and up to maximum of 120 months)
  • False lumen status (dissection pathology)(Minimum of 60 months and up to maximum of 120 months)
  • False lumen perfusion (dissection pathology)(Minimum of 60 months and up to maximum of 120 months)

研究者

发起方
W.L.Gore & Associates
申办方类型
Industry
责任方
Sponsor

研究点 (18)

Loading locations...

相似试验